Aviva PLC reduced its position in Hologic, Inc. (NASDAQ:HOLX) by 4.5% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 131,982 shares of the medical equipment provider’s stock after selling 6,260 shares during the period. Aviva PLC’s holdings in Hologic were worth $5,409,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently added to or reduced their stakes in the business. Reilly Financial Advisors LLC grew its stake in Hologic by 3.7% in the 3rd quarter. Reilly Financial Advisors LLC now owns 39,430 shares of the medical equipment provider’s stock worth $1,616,000 after acquiring an additional 1,390 shares during the period. Sentry Investment Management LLC grew its stake in Hologic by 8.3% in the 2nd quarter. Sentry Investment Management LLC now owns 18,271 shares of the medical equipment provider’s stock worth $726,000 after acquiring an additional 1,394 shares during the period. CIBC Asset Management Inc grew its stake in Hologic by 4.1% in the 2nd quarter. CIBC Asset Management Inc now owns 38,603 shares of the medical equipment provider’s stock worth $1,534,000 after acquiring an additional 1,504 shares during the period. Prudential Financial Inc. grew its stake in Hologic by 0.5% in the 3rd quarter. Prudential Financial Inc. now owns 300,094 shares of the medical equipment provider’s stock worth $12,298,000 after acquiring an additional 1,530 shares during the period. Finally, Majedie Asset Management Ltd grew its stake in Hologic by 1.5% in the 3rd quarter. Majedie Asset Management Ltd now owns 105,302 shares of the medical equipment provider’s stock worth $4,315,000 after acquiring an additional 1,589 shares during the period. 91.73% of the stock is owned by hedge funds and other institutional investors.
NASDAQ:HOLX opened at $41.98 on Friday. The company has a current ratio of 1.23, a quick ratio of 0.95 and a debt-to-equity ratio of 1.12. The firm has a market cap of $12.70 billion, a P/E ratio of 18.83, a price-to-earnings-growth ratio of 2.03 and a beta of 0.69. Hologic, Inc. has a twelve month low of $35.10 and a twelve month high of $45.17.
Hologic (NASDAQ:HOLX) last posted its earnings results on Wednesday, November 7th. The medical equipment provider reported $0.58 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.59 by ($0.01). The business had revenue of $813.50 million for the quarter, compared to analyst estimates of $808.63 million. Hologic had a negative net margin of 3.46% and a positive return on equity of 23.52%. The business’s revenue was up 1.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.50 EPS. Sell-side analysts forecast that Hologic, Inc. will post 2.4 EPS for the current year.
A number of equities analysts have weighed in on HOLX shares. BidaskClub upgraded shares of Hologic from a “buy” rating to a “strong-buy” rating in a report on Friday, October 19th. Bank of America lowered shares of Hologic from a “buy” rating to a “neutral” rating and decreased their price target for the company from $47.00 to $42.00 in a report on Thursday, September 13th. Needham & Company LLC reiterated a “buy” rating and issued a $48.00 price target on shares of Hologic in a report on Thursday, September 27th. Canaccord Genuity decreased their price target on shares of Hologic from $41.00 to $40.00 and set a “hold” rating on the stock in a report on Thursday, September 13th. Finally, Morgan Stanley decreased their price target on shares of Hologic from $47.00 to $44.00 and set an “equal weight” rating on the stock in a report on Thursday, October 11th. Eleven analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Hologic has a consensus rating of “Hold” and an average price target of $44.53.
In related news, CFO Karleen Marie Oberton sold 1,312 shares of Hologic stock in a transaction on Thursday, November 8th. The shares were sold at an average price of $41.90, for a total transaction of $54,972.80. Following the transaction, the chief financial officer now owns 10,206 shares in the company, valued at approximately $427,631.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Christiana Stamoulis sold 13,257 shares of Hologic stock in a transaction on Wednesday, November 28th. The shares were sold at an average price of $44.50, for a total transaction of $589,936.50. Following the transaction, the director now owns 48,296 shares in the company, valued at approximately $2,149,172. The disclosure for this sale can be found here. Insiders have sold a total of 79,276 shares of company stock worth $3,311,802 in the last 90 days. Company insiders own 0.79% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This story was first reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://www.americanbankingnews.com/2018/12/08/hologic-inc-holx-holdings-reduced-by-aviva-plc.html.
Hologic Company Profile
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
Featured Story: Hedge Funds
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.